WAY Q3 2024: 109% Retention, Warns of Q4 Revenue Normalization
- Robust Revenue and Client Growth: The Q&A highlighted strong revenue performance driven by rapid onboarding and effective cross-selling, with new and existing clients contributing to incremental growth above normal levels.
- Consistent Client Retention: Management reaffirmed a solid net revenue retention rate of 109%, consistent over 13 quarters, demonstrating strong customer stickiness and opportunities for further upsell.
- Innovative & Efficiency-Driven Strategy: Executives emphasized ongoing generative AI initiatives and operational improvements aimed at reducing claim denials and boosting efficiency, setting the stage for long-term margin expansion.
- Revenue normalization risk: Guidance highlights that revenue from patient payment volumes, elevated this quarter, is expected to normalize in Q4, potentially reducing future top‐line performance.
- Unsustainable rapid onboarding benefits: The one‐time $12 million boost from accelerated client onboarding driven by a competitor’s cyber event may not be repeatable, raising concerns over the durability of this revenue uplift.
- Extended sales cycle risk: Increasing complexity in RFPs—with more decision drivers and involvement of multiple stakeholders—could prolong sales cycles and delay future revenue recognition.
-
Revenue Guidance
Q: How stable is Q4 revenue?
A: Management explained that although Q3 volumes were above expectations due to seasonality and a pull-forward effect, they expect Q4 to normalize, aligning with their full-year guidance. -
Margin Efficiency
Q: Can operating margins improve further?
A: They maintained a robust 40% EBITDA margin even with full public expenses, and are focused on cost reduction measures—like lowering payment fees and optimizing payer networks—to bolster efficiency while balancing reinvestment and deleveraging. -
Rapid Onboarding
Q: What drove the $12M revenue bump?
A: The $12M revenue boost came from rapidly onboarding new clients and efficiently transitioning existing ones amid a competitor’s cyber event, reflecting both new acquisitions and internal cross-sell efforts that should stabilize over time. -
Demand Sustainability
Q: Is the elevated demand sustainable?
A: Management noted the post-cyber event demand remains robust, supported by a growing sales pipeline and continued cross-sell activity, though they remain cautious about long-term forecasts. -
Onboarding Efficiency
Q: Can rapid onboarding improve future efficiency?
A: They reported impressive onboarding speeds—sometimes in as little as 3 days—which has provided valuable learnings to refine processes, with potential further gains expected from AI and digital enhancements. -
Sales Cycle
Q: Are complex RFPs delaying sales?
A: While RFPs have become more complex and involve more stakeholders, management believes that the inherent longer decision cycles in large health systems keep the sales cycle within normal, expected durations. -
Claim Denials
Q: Are claim denials trending downward?
A: They highlighted that their platform achieves market-leading first-pass claim acceptance, and continuous improvements—including AI-driven appeal management—are expected to further reduce denial rates. -
Client Conference
Q: What did higher conference attendance indicate?
A: The 50% increase in attendance at their in-person event underscores strengthened client engagement and positive momentum in client relationships, although specific expansion metrics were not detailed. -
Competitive Edge
Q: How do you fare against modern competitors?
A: Management underscored that clients are increasingly favoring their integrated, cloud-based platform over legacy solutions, with stable win rates reinforcing their strong competitive positioning in a fragmented market.
Research analysts covering Waystar Holding.